Besivance Ophthalmic Solution: Advanced Bacterial Conjunctivitis Treatment
| Product dosage: 5 ml | |||
|---|---|---|---|
| Package (num) | Per flacon | Price | Buy |
| 2 | $22.59 | $45.18 (0%) | 🛒 Add to cart |
| 3 | $19.75 | $67.77 $59.24 (13%) | 🛒 Add to cart |
| 4 | $19.33 | $90.36 $77.31 (14%) | 🛒 Add to cart |
| 5 | $17.67
Best per flacon | $112.95 $88.35 (22%) | 🛒 Add to cart |
Synonyms | |||
Besivance (besifloxacin ophthalmic suspension) 0.6% is a prescription ophthalmic solution indicated for the treatment of bacterial conjunctivitis. As a broad-spectrum fluoroquinolone antimicrobial, it is specifically formulated to target and eliminate a wide range of ocular pathogens. Its unique suspension formulation is designed to enhance ocular surface contact time, potentially improving efficacy. This product is intended for use in patients 1 year of age and older, providing a trusted option for both pediatric and adult populations under professional supervision.
Features
- Active ingredient: Besifloxacin 0.6% (6 mg/mL)
- Pharmaceutical form: Sterile ophthalmic suspension
- Preservative: Benzalkonium chloride 0.01%
- Presentation: 5 mL in a white low-density polyethylene bottle with a controlled dropper tip
- pH: Approximately 6.8 (range 6.0–7.5)
- Osmolality: Approximately 300 mOsm/kg
- Mechanism: Inhibits bacterial DNA gyrase and topoisomerase IV
Benefits
- Demonstrates potent in vitro activity against key gram-positive and gram-negative ocular pathogens, including resistant strains
- Formulated as a mucoadhesive suspension to prolong residence time on the ocular surface
- Low systemic absorption minimizes risk of systemic adverse effects
- Convenient twice-daily dosing regimen supports patient adherence
- Effective clinical response observed in pediatric and adult populations
- Rapid bactericidal action helps reduce bacterial load and inflammatory symptoms
Common use
Besivance is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: Aerococcus viridans, Corynebacterium pseudodiphtheriticum, Corynebacterium striatum, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus warneri, Streptococcus mitis, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius. Clinical trials have demonstrated efficacy against both methicillin-susceptible and methicillin-resistant staphylococcal isolates.
Dosage and direction
The recommended dosage for patients 1 year of age and older is one drop in the affected eye(s) twice daily, approximately 8 to 12 hours apart, for 7 days. Patients should be instructed to shake the bottle well before each use. Contact lenses should be removed prior to administration and may be reinserted 15 minutes following instillation. To prevent contamination of the solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip. If more than one ophthalmic medication is being used, the solutions should be administered at least 5 minutes apart.
Precautions
As with all antibacterial preparations, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. The preservative benzalkonium chloride may be absorbed by soft contact lenses and may cause eye irritation. Patients should be instructed to avoid contaminating the applicator tip with material from the eye, fingers, or other sources. If solution changes color or becomes cloudy, the product should not be used.
Contraindications
Besivance is contraindicated in patients with a history of hypersensitivity to besifloxacin, to other quinolones, or to any of the components in this medication. Hypersensitivity reactions may include anaphylaxis, angioedema, bronchospasm, and skin reactions. Cross-sensitivity to other quinolones has been documented; therefore, besifloxacin should be avoided in patients who have demonstrated hypersensitivity to other quinolone antibacterial drugs.
Possible side effects
The most common adverse reactions occurring in approximately 1-5% of patients included: blurred vision, eye irritation, eye pain, eye redness, and headache. Less common reactions (occurring in <1% of patients) included: conjunctival hemorrhage, dry eye, eye pruritus, increased lacrimation, ocular hyperemia, and reduced visual acuity. Rare cases of corneal infiltrates and allergic reactions have been reported. As with other fluoroquinolones, serious and occasionally fatal hypersensitivity reactions have been reported, some following the first dose.
Drug interaction
Specific drug interaction studies have not been conducted with Besivance. However, the systemic concentration of besifloxacin following ocular administration is low. In clinical trials, Besivance was administered concomitantly with other topical ophthalmedicinal products without evidence of adverse interactions. When multiple topical ophthalmic medications are required, they should be administered at least 5 minutes apart. The compatibility of Besivance with other topical ophthalmedicinal products has not been established.
Missed dose
If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should be advised not to instill two doses at the same time to make up for a missed dose. Consistent adherence to the prescribed dosing regimen is important for clinical efficacy and to minimize the development of bacterial resistance.
Overdose
Ocular overdose of Besivance may be flushed from the eye(s) with warm tap water. Due to the low systemic exposure following ocular administration, systemic adverse effects are unlikely. However, if the solution is ingested orally, symptomatic treatment should be instituted. In case of accidental ingestion, the patient should drink plenty of water and seek medical attention if necessary. No specific antidote exists for besifloxacin overdose.
Storage
Store at 2°C to 25°C (36°F to 77°F). Do not freeze. Keep the bottle tightly closed when not in use. Protect from light. Discard the bottle within 28 days after opening. Do not use if the solution has changed color or become cloudy. Keep out of reach of children. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Besivance is a prescription medication that should be used only under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for complete information regarding indications, dosage, warnings, and precautions. Individual results may vary. The safety and effectiveness of Besivance in children below 1 year of age have not been established.
Reviews
Clinical studies have demonstrated that Besivance ophthalmic solution is effective in the treatment of bacterial conjunctivitis. In randomized, double-masked, vehicle-controlled studies, patients treated with Besivance showed significantly higher rates of clinical resolution and microbial eradication compared to vehicle-treated patients. The solution was generally well-tolerated with a favorable safety profile. Many ophthalmologists report satisfactory clinical outcomes with Besivance, particularly noting its efficacy against resistant organisms and convenient dosing schedule. Patient satisfaction surveys indicate good tolerability and ease of administration.